[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112017014552A2 - ?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado? - Google Patents

?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado?

Info

Publication number
BR112017014552A2
BR112017014552A2 BR112017014552A BR112017014552A BR112017014552A2 BR 112017014552 A2 BR112017014552 A2 BR 112017014552A2 BR 112017014552 A BR112017014552 A BR 112017014552A BR 112017014552 A BR112017014552 A BR 112017014552A BR 112017014552 A2 BR112017014552 A2 BR 112017014552A2
Authority
BR
Brazil
Prior art keywords
liver
triglycerides
decrease
reduction
producing
Prior art date
Application number
BR112017014552A
Other languages
English (en)
Inventor
Henriksen Kim
Vietz Andreassen Kim
Karsdal Morten
Toftegaard Hjuler Sara
GYDESEN Sofie
Original Assignee
Keybioscience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keybioscience Ag filed Critical Keybioscience Ag
Publication of BR112017014552A2 publication Critical patent/BR112017014552A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

análogos de calcitonina como um medicamento para produzir uma diminuição em triglicerídeos no fígado ou para reduzir o acúmulo de gordura no fígado de um indivíduo.
BR112017014552A 2015-01-08 2016-01-07 ?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado? BR112017014552A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1500263.7A GB201500263D0 (en) 2015-01-08 2015-01-08 Calcitonin analogues for treating diseases and disorders
PCT/EP2016/050186 WO2016110525A1 (en) 2015-01-08 2016-01-07 Calcitonin analogues for treating diseases and disorders

Publications (1)

Publication Number Publication Date
BR112017014552A2 true BR112017014552A2 (pt) 2018-05-15

Family

ID=52597359

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014552A BR112017014552A2 (pt) 2015-01-08 2016-01-07 ?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado?

Country Status (17)

Country Link
US (2) US10350272B2 (pt)
EP (1) EP3247383A1 (pt)
JP (1) JP2018502854A (pt)
KR (1) KR20170120576A (pt)
CN (1) CN107206056A (pt)
AU (1) AU2016205994A1 (pt)
BR (1) BR112017014552A2 (pt)
CA (1) CA2969293A1 (pt)
CL (1) CL2017001773A1 (pt)
CO (1) CO2017007007A2 (pt)
EA (1) EA201791154A1 (pt)
GB (1) GB201500263D0 (pt)
IL (1) IL253026A0 (pt)
MX (1) MX2017008755A (pt)
PE (1) PE20171320A1 (pt)
PH (1) PH12017500988A1 (pt)
WO (1) WO2016110525A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201704429D0 (en) * 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) * 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813677D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1137431A1 (en) 1998-12-04 2001-10-04 Provalis UK Limited Pharmaceutical compositions containing insulin
ATE288415T1 (de) 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
IE20040202A1 (en) 2003-03-28 2004-10-06 Sigmoid Biotechnologies Ltd Solid oral dosage form containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
CA2532565C (en) 2003-07-23 2012-05-08 Novartis Ag Use of calcitonin in osteoarthritis
JP2007523050A (ja) 2003-09-17 2007-08-16 カイアズマ・リミテッド 生物学的障壁を通した透過を容易にすることのできる組成物
JP2008506750A (ja) 2004-07-22 2008-03-06 ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー チオール基を含む化合物の排出ポンプ抑制剤としての使用
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
US8815583B2 (en) 2005-06-24 2014-08-26 Enteris Biopharma, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
JP5222727B2 (ja) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
PL1834635T3 (pl) 2006-03-13 2012-01-31 Advancell Advanced In Vitro Cell Tech S A Stabilne układy nanokapsułek do podawania cząsteczek aktywnych
EP2526950A1 (en) 2006-04-07 2012-11-28 Merrion Research III Limited Solid oral dosage form containing an enhancer
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
CA2750035C (en) * 2009-01-22 2018-02-27 Unigene Laboratories Inc. Treatment for obesity
CA2854175A1 (en) 2011-11-02 2013-05-10 Keybioscience Ag Peptide analogs for treating diseases and disorders
BR112016010643A2 (pt) * 2013-11-14 2017-12-05 Keybioscience Ag peptídeo

Also Published As

Publication number Publication date
EP3247383A1 (en) 2017-11-29
US20190328843A1 (en) 2019-10-31
GB201500263D0 (en) 2015-02-25
PH12017500988A1 (en) 2017-12-18
JP2018502854A (ja) 2018-02-01
US20180264085A1 (en) 2018-09-20
CN107206056A (zh) 2017-09-26
PE20171320A1 (es) 2017-09-07
AU2016205994A1 (en) 2017-06-15
MX2017008755A (es) 2017-11-17
WO2016110525A1 (en) 2016-07-14
CO2017007007A2 (es) 2018-01-31
KR20170120576A (ko) 2017-10-31
IL253026A0 (en) 2017-08-31
EA201791154A1 (ru) 2017-09-29
CL2017001773A1 (es) 2018-03-09
US10350272B2 (en) 2019-07-16
CA2969293A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
ZA201608077B (en) Combination, composition, and method of administering the combination or composition to animals
GT201700072A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
PL3349783T3 (pl) Kompozycje i sposoby do leczenia chorób
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
BR112016020618A8 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
PL3273942T3 (pl) Plaster mikroigłowy do dostarczania składnika aktywnego do skóry
NI201600071A (es) Compuestos de inhibidor de autotaxina
IL251530A0 (en) Use of cannabinoids in the treatment of skeletal muscle atrophy
MX2018003174A (es) Metodos para tratar enfermedades inflamatorias.
MX2017006113A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
IL265719A (en) Fabp4 as a therapeutic target in skin diseases
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CL2018001104A1 (es) Composición para el cuidado de la piel y procedimiento asociado.
BR112016028918A2 (pt) tratamento de hipertrigliceridemia grave
BR112017014552A2 (pt) ?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado?
PH12016502311A1 (en) Omega-3 analogues
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
LT3229790T (lt) Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme
PH12017501979A1 (en) Pharmaceutical compound
MX374875B (es) Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevención de la acumulación de grasa.
DOP2015000290A (es) Benzoxazoles sustituidos
AU360949S (en) A component for an artificial honeycomb
HK1240080A1 (en) Calcitonin analogues for treating diseases and disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements